Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166242 | 1.00 | ADRB3 (0.44) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166297 | 1.00 | ADRB3 (0.44) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166365 | 0.92 | ACACB (0.45) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166253 | 0.92 | ACACB (0.45) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166309 | 0.92 | ACACB (0.45) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166280 | 0.92 | ACACB (0.45) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166224 | 0.90 | ACACB (0.46) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166305 | 0.90 | ACACB (0.46) | ADRB3ADRB1APPACACBKDM4E | |
| SCHEMBL27166267 | 0.86 | ADRB1 (0.47) | ADRB3ADRB1ACACBKDM4EALDH1A1 | |
| SCHEMBL27166314 | 0.86 | ADRB1 (0.47) | ADRB3ADRB1ACACBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AG (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4583925-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052573-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335840-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4335461-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | GBA1, GBA3, GLS2 | ADRB3 761/4885ADRB1 2159/4885APP 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.